← Eichor
Study identifier: NCT05791448 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease

Condition: Advanced Cholangiocarcinoma · Advanced Hepatocellular Carcinoma · Advanced Malignant Solid Neoplasm  ·  Sponsor: University of Southern California

PhasePhase 1
Planned participants36
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This phase I trial tests the safety, side effects, and best dose of a new intervention, AU409, in treating patients with primary liver cancers that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or advanced solid tumors that have spread to the liver (liver metastatic disease). AU409 may stop cancer from growing and spreading. This trial may help researchers determine if AU409 is safe and effective in treating patients with liver cancers and solid tumors with liver metastatic disease.

This description comes directly from the study's public registry record.

Talk to the study team

Xiomara Menendez, RN  ·  323-865-0212  ·  Xiomara.Menendez@med.usc.edu

Always discuss trial participation with your own doctor first.

Locations (2)

Los Angeles County-USC Medical CenterLos Angeles, California, United StatesRecruiting
USC / Norris Comprehensive Cancer CenterLos Angeles, California, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05791448